Novo Nordisk to join elite Stoxx Europe 50 index

Rating is likely to impact positively on share price

The medicinal giant Novo Nordisk will soon take its place on the prestigious Euro Stoxx 50 index, the leading rating system of European blue chips, where it will join the likes of Bayer, Shell, AB-Inbev and HSBC, Børsen reports.

 READ MORE: Novo Nordisk reports recordbreaking year

On June 22, Novo Nordisk will bump the British bank Standard Chartered from the list of high-flying European companies. The promotion is likely to impact positively on the company’s share price, according to Børsen, as a number of investment funds structure their portfolio to match the index.

The company’s stock has been steadily climbing since January, following a year in which Novo Nordisk earned the equivalent of four million kroner per hour, day and night.

With a market value of 1,000 billion kroner, Novo will be the seventh biggest company on the Euro Stoxx 50.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.